REG - e-Therapeutics plc - Strategic RWE collaboration with Arcturis

E-TherapeuticsAnnouncement

02/11/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231102:nRSB1058Sa&default-theme=true

RNS Number : 1058S  e-Therapeutics plc  02 November 2023

 

e-therapeutics plc

("e-therapeutics" or the "Company")

 

Strategic RWE collaboration with Arcturis

 

 

London, UK, 02 November 2023 - e-therapeutics plc (AIM: ETX; OTCQX; ETXPF),
a company integrating computational power and biological data to discover
life-transforming RNAi medicines, today announces a strategic collaboration
with Arcturis Data Limited, a UK data company with a high quality and enriched
real-world data platform. The companies will integrate Arcturis' Real-World
Evidence (RWE), which utilises a platform comprised of high quality,
clinically-rich real-world data, and analytical expertise derived from their
unique access to anonymised patient data with e-therapeutics' computational
biology platform, HepNet™. The collaboration will focus on delivering novel
insights to support innovative therapies for patients with metabolic
dysfunction and associated fatty liver disease, including nonalcoholic
steatohepatitis (NASH).

 

Arcturis' RWE outputs will be analysed by e-therapeutics using HepNet™, its
proprietary suite of artificial intelligence (AI)-driven algorithms and
hepatocyte-centric data sources, to drive the discovery and development of
innovative RNAi medicines for the treatment of NASH and related disorders.
Under the terms of the agreement, e-therapeutics will have exclusive rights to
nominate novel gene targets derived from the collaboration to prosecute
genetic medicines using its GalOmic™ RNAi platform.

 

Ali Mortazavi, Chief Executive Officer of e-therapeutics, commented: "This is
an important strategic collaboration which enables us to access real-world
insights generated from patient data including electronic health records,
imaging and biomarker data, and integrate these insights into HepNet™. This
effort complements ongoing work at e-therapeutics in metabolic diseases, and
we believe that the collaboration will unveil unique insights into the
biological mechanisms driving NASH that we can target to deliver effective
RNAi medicines to patients."

 

Alex Snow, Chief Executive Officer of Arcturis, said: "We are delighted to
start this collaboration with e-therapeutics. The Arcturis analytics platform
derives evidence from anonymised and highly curated longitudinal and granular
health data and we are excited to integrate these real-world insights with
HepNet™, to deliver powerful findings that may lead to novel and innovative
RNAi medicines."

 

 

Enquiries:

 

 e-therapeutics plc
 Ali Mortazavi, CEO                                                                    Tel: +44 (0)20 4551 8888

 Timothy Bretherton,                                                                   www.etherapeutics.co.uk (http://www.etherapeutics.co.uk)
 CFO

      SP Angel Corporate Finance LLP                                                   Tel: +44(0)20 3470 0470
 Nominated Adviser and Broker
 Matthew Johnson/Harry Davies-Ball (Corporate Finance)
 Vadim Alexandre/Rob Rees (Corporate Broking)

 

 

About Arcturis Data Limited

 

Arcturis is a real-world data company that works alongside clinical and
industry experts to support delivery of research across all phases of the
clinical development pipeline, covering all conditions and treatment types.
Arcturis are experts in applying both traditional and innovative real-world
evidence techniques, covering medical statistics, machine learning, and data
science approaches. Arcturis' priority is working with high quality, enriched
real-world data that is integrated with important clinical context and built
on scientific principles, with the aim of delivering robust outputs for global
partners, contributing to improving clinical research, and enhancing patient
outcomes. Arcturis is based in Oxfordshire. For more information, visit
www.arcturisdata.com (http://www.arcturisdata.com) .

 

 

About e-therapeutics plc

 

e-therapeutics plc ("ETX") integrates computational power and biology
information to discover life-transforming RNAi medicines. The Company's
technology uses computation to capture and model human biology, identify novel
targets, and develop RNAi medicines against those targets that can be rapidly
progressed to the clinic.

 

ETX's proprietary HepNet™ platform enables the generation and analysis of
biological network models, providing a novel and mechanistic approach to drug
discovery. This approach explicitly considers the true complexity of biology
to make more reliable predictions from large complex data sets and ETX's
proprietary hepatocyte knowledgebase - the world's most comprehensive and
integrated hepatocyte-centric data resource.  The Company generates,
prioritises, and tests millions of hypotheses in silico to identify better
therapeutic targets with higher confidence.

 

GalOmic™, ETX's proprietary RNAi platform, enables targeted delivery to
hepatocytes in the liver and the specific silencing of novel
disease-associated genes, identified by HepNet™. The focus on hepatocytes
offers the opportunity to tackle a wide variety of diseases.  The liver is a
highly metabolically active organ which performs a key role in many biological
processes and vital functions crucial for human health. ETX's GalOmic™
constructs have demonstrated compelling in vivo performance in terms of depth
of gene silencing and duration of action.

 

The Company is progressing a pipeline of first-in-class RNAi candidates across
a variety of therapeutic areas with high unmet need, including preclinical
programs in cardiometabolic and metabolic diseases, haemophilia, and other
undisclosed indications. ETX has also partnered with biopharma companies such
as Novo Nordisk, Galapagos NV and iTeos Therapeutics using its computational
network biology approach across a diverse range of drug discovery projects.

 

The Company is based in London, UK and listed on the Alternative Investment
Market of the London Stock Exchange ("AIM"), with ticker symbol ETX.
e-therapeutics is also traded on the OTCQX Best Market (OTCQX) in the United
States, under ticker symbol ETXPF.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEAXFFEANDFFA